Cargando…
Biomanufacturing readiness levels [BRL]—A shared vocabulary for biopharmaceutical technology development and commercialization
The Manufacturing Readiness Levels (MRLs) developed by the Department of Defense are well‐established tools for describing the maturity of new technologies resulting from government‐sponsored Research and Development programs, from the concept phase to commercial deployment. While MRLs are generally...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826509/ https://www.ncbi.nlm.nih.gov/pubmed/36071569 http://dx.doi.org/10.1002/bit.28227 |
_version_ | 1784866869109325824 |
---|---|
author | Kedia, Sandeep B. Baker, Jeffrey C. Carbonell, Ruben G. Lee, Kelvin H. Roberts, Christopher J. Erickson, John Schiel, John E. Rogers, Kelley Schaefer, Gene Pluschkell, Stefanie |
author_facet | Kedia, Sandeep B. Baker, Jeffrey C. Carbonell, Ruben G. Lee, Kelvin H. Roberts, Christopher J. Erickson, John Schiel, John E. Rogers, Kelley Schaefer, Gene Pluschkell, Stefanie |
author_sort | Kedia, Sandeep B. |
collection | PubMed |
description | The Manufacturing Readiness Levels (MRLs) developed by the Department of Defense are well‐established tools for describing the maturity of new technologies resulting from government‐sponsored Research and Development programs, from the concept phase to commercial deployment. While MRLs are generally applicable to a wide range of industries and technologies, there is significant value in offering an industry‐specific view on how the basic principles may be applied to biomanufacturing. This paper describes Biomanufacturing Readiness Levels (BRLs) developed by the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), a public/private partnership that is part of the Manufacturing USA network. NIIMBL brings together private, federal, nonprofit, and academic stakeholders to accelerate the deployment of innovative technologies for biopharmaceutical production and to educate and train a world‐leading biomanufacturing workforce. We anticipate that these BRLs will lay the groundwork for a shared vocabulary for assessment of technology maturity and readiness for commercial biomanufacturing that effectively meets the needs of this critical, specialized, and highly regulated industry. |
format | Online Article Text |
id | pubmed-9826509 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98265092023-01-09 Biomanufacturing readiness levels [BRL]—A shared vocabulary for biopharmaceutical technology development and commercialization Kedia, Sandeep B. Baker, Jeffrey C. Carbonell, Ruben G. Lee, Kelvin H. Roberts, Christopher J. Erickson, John Schiel, John E. Rogers, Kelley Schaefer, Gene Pluschkell, Stefanie Biotechnol Bioeng ARTICLES The Manufacturing Readiness Levels (MRLs) developed by the Department of Defense are well‐established tools for describing the maturity of new technologies resulting from government‐sponsored Research and Development programs, from the concept phase to commercial deployment. While MRLs are generally applicable to a wide range of industries and technologies, there is significant value in offering an industry‐specific view on how the basic principles may be applied to biomanufacturing. This paper describes Biomanufacturing Readiness Levels (BRLs) developed by the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), a public/private partnership that is part of the Manufacturing USA network. NIIMBL brings together private, federal, nonprofit, and academic stakeholders to accelerate the deployment of innovative technologies for biopharmaceutical production and to educate and train a world‐leading biomanufacturing workforce. We anticipate that these BRLs will lay the groundwork for a shared vocabulary for assessment of technology maturity and readiness for commercial biomanufacturing that effectively meets the needs of this critical, specialized, and highly regulated industry. John Wiley and Sons Inc. 2022-09-21 2022-12 /pmc/articles/PMC9826509/ /pubmed/36071569 http://dx.doi.org/10.1002/bit.28227 Text en © 2022 The Authors. Biotechnology and Bioengineering published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | ARTICLES Kedia, Sandeep B. Baker, Jeffrey C. Carbonell, Ruben G. Lee, Kelvin H. Roberts, Christopher J. Erickson, John Schiel, John E. Rogers, Kelley Schaefer, Gene Pluschkell, Stefanie Biomanufacturing readiness levels [BRL]—A shared vocabulary for biopharmaceutical technology development and commercialization |
title | Biomanufacturing readiness levels [BRL]—A shared vocabulary for biopharmaceutical technology development and commercialization |
title_full | Biomanufacturing readiness levels [BRL]—A shared vocabulary for biopharmaceutical technology development and commercialization |
title_fullStr | Biomanufacturing readiness levels [BRL]—A shared vocabulary for biopharmaceutical technology development and commercialization |
title_full_unstemmed | Biomanufacturing readiness levels [BRL]—A shared vocabulary for biopharmaceutical technology development and commercialization |
title_short | Biomanufacturing readiness levels [BRL]—A shared vocabulary for biopharmaceutical technology development and commercialization |
title_sort | biomanufacturing readiness levels [brl]—a shared vocabulary for biopharmaceutical technology development and commercialization |
topic | ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826509/ https://www.ncbi.nlm.nih.gov/pubmed/36071569 http://dx.doi.org/10.1002/bit.28227 |
work_keys_str_mv | AT kediasandeepb biomanufacturingreadinesslevelsbrlasharedvocabularyforbiopharmaceuticaltechnologydevelopmentandcommercialization AT bakerjeffreyc biomanufacturingreadinesslevelsbrlasharedvocabularyforbiopharmaceuticaltechnologydevelopmentandcommercialization AT carbonellrubeng biomanufacturingreadinesslevelsbrlasharedvocabularyforbiopharmaceuticaltechnologydevelopmentandcommercialization AT leekelvinh biomanufacturingreadinesslevelsbrlasharedvocabularyforbiopharmaceuticaltechnologydevelopmentandcommercialization AT robertschristopherj biomanufacturingreadinesslevelsbrlasharedvocabularyforbiopharmaceuticaltechnologydevelopmentandcommercialization AT ericksonjohn biomanufacturingreadinesslevelsbrlasharedvocabularyforbiopharmaceuticaltechnologydevelopmentandcommercialization AT schieljohne biomanufacturingreadinesslevelsbrlasharedvocabularyforbiopharmaceuticaltechnologydevelopmentandcommercialization AT rogerskelley biomanufacturingreadinesslevelsbrlasharedvocabularyforbiopharmaceuticaltechnologydevelopmentandcommercialization AT schaefergene biomanufacturingreadinesslevelsbrlasharedvocabularyforbiopharmaceuticaltechnologydevelopmentandcommercialization AT pluschkellstefanie biomanufacturingreadinesslevelsbrlasharedvocabularyforbiopharmaceuticaltechnologydevelopmentandcommercialization |